Addressing Remaining Unmet Needs in mCRPC

Panelists discuss how future trials in metastatic castration-resistant prostate cancer (mCRPC) should focus on developing reliable biomarker-driven treatment selection strategies to optimize sequencing decisions and identify which patients will benefit most from specific therapies or combinations, particularly as the treatment landscape becomes increasingly complex.

EP: 1.The Contemporary Treatment Landscape of mCRPC

EP: 2.Treatment Selection and the Use of Combination Therapies in mCRPC

EP: 3.The PEACE-3 Trial

EP: 4.The Safety Profile of RAD-ENZ

EP: 5.Applying Results From PEACE-3 to Your Patient Population

EP: 6.The Future of RAD-ENZ Combination Therapy

EP: 7.Treatment Selection for mCRPC

EP: 8.Clinical Perspectives on Early Use of RAD-ENZ

EP: 9.The DORA Trial

Now Viewing

EP: 10.Addressing Remaining Unmet Needs in mCRPC

Video content above is prompted by the following:

• What is one key unmet need or clinical utility in the treatment of mCRPC that future trials should address?

Related Videos

Related Content

Advertisement

June 2nd 2025

Survey: New NMIBC treatments face slow uptake

Benjamin P. Saylor

Results of an exclusive Urology Times survey point to urologists preferring intravesical chemotherapy for treating BCG-unresponsive NMIBC.

July 15th 2025

Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD

Amy M. Pearlman, MD

Mulhall offers an unfiltered, evidence-based deep dive into testosterone evaluation and treatment nuances.

April 27th 2025

Sildenafil/Clomipramine Combo Boosts Outcomes in Premature Ejaculation

Patrick Campbell

A phase 3 trial reveals a combination therapy for premature ejaculation significantly enhances treatment outcomes.

June 30th 2025

Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD

Amy M. Pearlman, MD

Pearlman and Parekattil dig deep into novel surgical and non-surgical approaches to chronic orchialgia and pelvic pain.

April 26th 2025

ADAM, a long-term, injectable male birth control, shows promise at AUA 2025

Patrick Campbell

A groundbreaking male contraceptive shows promising safety results, offering a reversible option for couples seeking effective birth control.

April 26th 2025

TikTok, social media does more harm than good for prostate cancer education

Patrick Campbell

Social media spreads significant misinformation about prostate cancer. Experts urge clinicians to provide trusted information sources.

Related Content

Advertisement

June 2nd 2025

Survey: New NMIBC treatments face slow uptake

Benjamin P. Saylor

Results of an exclusive Urology Times survey point to urologists preferring intravesical chemotherapy for treating BCG-unresponsive NMIBC.

July 15th 2025

Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD

Amy M. Pearlman, MD

Mulhall offers an unfiltered, evidence-based deep dive into testosterone evaluation and treatment nuances.

April 27th 2025

Sildenafil/Clomipramine Combo Boosts Outcomes in Premature Ejaculation

Patrick Campbell

A phase 3 trial reveals a combination therapy for premature ejaculation significantly enhances treatment outcomes.

June 30th 2025

Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD

Amy M. Pearlman, MD

Pearlman and Parekattil dig deep into novel surgical and non-surgical approaches to chronic orchialgia and pelvic pain.

April 26th 2025

ADAM, a long-term, injectable male birth control, shows promise at AUA 2025

Patrick Campbell

A groundbreaking male contraceptive shows promising safety results, offering a reversible option for couples seeking effective birth control.

April 26th 2025

TikTok, social media does more harm than good for prostate cancer education

Patrick Campbell

Social media spreads significant misinformation about prostate cancer. Experts urge clinicians to provide trusted information sources.